Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $72.5 million.

  • UNITED THERAPEUTICS's Depreciation & Amortization (CF) rose 14.66% to $21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.5 million, marking a year-over-year increase of 24.06%. This contributed to the annual value of $72.5 million for FY2024, which is 36.28% up from last year.
  • According to the latest figures from FY2024, UNITED THERAPEUTICS's Depreciation & Amortization (CF) is $72.5 million, which was up 36.28% from $53.2 million recorded in FY2023.
  • UNITED THERAPEUTICS's 5-year Depreciation & Amortization (CF) high stood at $72.5 million for FY2024, and its period low was $49.9 million during FY2020.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $53.2 million (2023), whereas its average is $59.0 million.
  • Per our database at Business Quant, UNITED THERAPEUTICS's Depreciation & Amortization (CF) fell by 0.00% in 2021 and then skyrocketed by 36.28% in 2024.
  • UNITED THERAPEUTICS's Depreciation & Amortization (CF) (MRY) stood at $49.9 million in 2020, then dropped by 0.00% to $49.9 million in 2021, then grew by 2.81% to $51.3 million in 2022, then increased by 3.70% to $53.2 million in 2023, then skyrocketed by 36.28% to $72.5 million in 2024.
  • Its Depreciation & Amortization (CF) was $72.5 million in FY2024, compared to $53.2 million in FY2023 and $51.3 million in FY2022.